|
1
|
Maxwell SA and Mousavi-Fard S:
Non-Hodgkin’s B-cell lymphoma: advances in molecular strategies
targeting drug resistance. Exp Biol Med (Maywood). 238:971–990.
2013.
|
|
2
|
Griffin MM and Morley N: Rituximab in the
treatment of non-Hodgkin’s lymphoma - a critical evaluation of
randomized controlled trials. Expert Opin Biol Ther. 13:803–811.
2013.
|
|
3
|
Goldman S, Smith L, Anderson JR, et al:
Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV
B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report.
Leukemia. 27:1174–1177. 2013.PubMed/NCBI
|
|
4
|
Hitz F, Fischer N, Pabst T, et al:
Rituximab, bendamustine, and lenalidomide in patients with
aggressive B cell lymphoma not eligible for high-dose chemotherapy
or anthracycline-based therapy: phase I results of the SAKK 38/08
trial. Ann Hematol. 92:1033–1040. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu PP, Wang Y, Shen Y, et al: Prognostic
factors of Chinese patients with T/NK-cell lymphoma: a single
institution study of 170 patients. Med Oncol. 29:2176–2182. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Friedberg JW, Byrtek M, Link BK, et al:
Effectiveness of first-line management strategies for stage I
follicular lymphoma: analysis of the National LymphoCare Study. J
Clin Oncol. 30:3368–3375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morin RD and Gascoyne RD: Newly identified
mechanisms in B-cell non-Hodgkin lymphomas uncovered by
next-generation sequencing. Semin Hematol. 50:303–313. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rehn S, Glimelius B, Strang P, et al:
Prognostic significance of flow cytometry studies in B-cell
non-Hodgkin lymphoma. Hematol Oncol. 8:1–12. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xue G and Hemmings BA: Phosphorylation of
basic helix-loop-helix transcription factor TWIST1 in development
and disease. Biochem Soc Trans. 40:90–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weiss MB, Abel EV, Mayberry MM, et al:
TWIST11 is an ERK1/2 effector that promotes invasion and regulates
MMP-1 expression in human melanoma cells. Cancer Res. 72:6382–6392.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roschewski M, Staudt LM and Wilson WH:
Diffuse large B-cell lymphoma-treatment approaches in the molecular
era. Nat Rev Clin Oncol. 11:12–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng GZ, Chan J, Wang Q, et al: TWIST1
transcriptionally up-regulates AKT2 in breast cancer cells leading
to increased migration, invasion, and resistance to paclitaxel.
Cancer Res. 67:1979–1987. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogura M, Hatake K, Ando K, et al: Phase I
study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus
rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Cancer Sci. 103:933–938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qin Q, Xu Y, He T, et al: Normal and
disease-related biological functions of TWIST11 and underlying
molecular mechanisms. Cell Res. 22:90–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takeuchi M, Sato Y and Yoshino T: The
frequency of malignant lymphoma subtypes based on World Health
Organization (WHO) classification. Nihon Rinsho. 72:436–440.
2014.PubMed/NCBI
|
|
16
|
Ciobanu A, Stanca O, Triantafyllidis I, et
al: Indolent lymphoma: diagnosis and prognosis in medical practice.
Maedica (Buchar). 8:338–342. 2013.PubMed/NCBI
|
|
17
|
Lange J and Burkhardt B: Treatment of
adolescents with aggressive B-cell malignancies: the pediatric
experience. Curr Hematol Malig Rep. 8:226–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Na YR, Lee JS, Lee SJ and Seok SH:
Interleukin-6-induced TWIST1 and N-cadherin enhance melanoma cell
metastasis. Melanoma Res. 23:434–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
